Phase 1 Study of the TRK Inhibitor Larotrectinib in Solid Tumors
MD Anderson Study Status
Larotrectinib (Vitrakvi, BAY2757556)
This research study is done to test the safety of the drug larotrectinib in adult cancer patients. The drug may be used to treat cancer with a change in a particular gene (NTRK1, NTRK2 or NTRK3), because it blocks the action of these genes in cancer cells. The study also investigates how the drug is absorbed and processed in the human body. This is the first study to test larotrectinib in humans with cancer, for whom no other effective therapy exists.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Solid Tumors Harboring NTRK Fusion
David Sanghyun Hong
Investigational Cancer Therapeutics
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.